Traditional Chinese Medicine
Europe · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Europe Travel Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Disease, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$500.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $749.1 Mn | — | — |
| 2025 (base) | $791.1 Mn | +$42.0 Mn | — |
| 2026 (forecast) | $835.4 Mn | +$44.3 Mn | +5.6% |
| 2027 (forecast) | $882.2 Mn | +$46.8 Mn | +11.5% |
| 2028 (forecast) | $931.6 Mn | +$49.4 Mn | +17.8% |
| 2029 (forecast) | $983.7 Mn | +$52.2 Mn | +24.4% |
| 2030 (forecast) | $1.04 Bn | +$55.1 Mn | +31.3% |
| 2031 (forecast) | $1.10 Bn | +$58.2 Mn | +38.7% |
| 2032 (forecast) | $1.16 Bn | +$61.4 Mn | +46.4% |
| 2033 (forecast) | $1.22 Bn | +$64.9 Mn | +54.6% |
| 2034 (forecast) | $1.29 Bn | +$68.5 Mn | +63.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $791.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.29 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Disease, channel and end user (see all) |
| Key players | Sanofi, Valneva, Bavarian Nordic, GSK PLC, Bharat Biotech (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Travel vaccines protect travellers against diseases common in other regions, such as typhoid, yellow fever, rabies and cholera.
Key segments of the travel Vaccines market include disease (Typhoid, Yellow Fever and Rabies) and channel (Travel Clinics, Pharmacies and Hospitals).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the travel Vaccines market.
New vaccines, rapid tests and public-private funding for neglected diseases give the travel Vaccines market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the travel Vaccines market.
The travel Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for travel Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Travel Vaccines right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 2 shared keywords
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Medical Devices · Europe
Medical Devices · Europe
OTC & Nutraceuticals · Europe
Medical Devices · Europe
Healthcare Services · Europe
Medical Devices · Europe